A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

September 1, 2027

Conditions

Congenital Erythropoietic Porphyria (CEP)

Interventions

DRUG

ATL-001 (Ciclopirox oral solution)

Daily administration of oral ATL-001